跳至主要内容
临床试验/NCT05569200
NCT05569200尚未招募不适用

The Clinical Trial About Treatment of Benign Uterus Myoma by Haifu Focused Ultrasound Tumor Therapeutic System.

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2022年12月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
10
试验地点
1
主要终点
Evaluation of tumour response

研究概览

简要总结

Uterine benign tumor including myoma is the most common female benign pelvic tumor. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) has been considered to be a minimal invasive treatment. The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In this trial, the investigators will observe the possibility of complication and tumor response of treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Benign uterine fibroids.
  • Women over the age of
  • Abdominal circumference <100 cm.
  • The largest fibroids are ≥ 4 cm.

排除标准

  • Pregnant women or those with positive pregnancy test results.
  • Those with other pelvic diseases.
  • Those with immune diseases.
  • There are unsuitable interfaces in the ultrasonic treatment path.
  • Those with tumor calcification.
  • People with severe heart, blood vessel and kidney disease.
  • Those with abnormal coagulation function and low platelets.
  • Type III fibroids according to Funaki classification

结局指标

主要结局

Evaluation of tumour response

时间窗: 3 month after treatment

Evaluation of tumour response according to the modified RECIST criteria by sequencing MR imaging

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

The Clinical Trial About Treatment of Benign Uterus... | 临床试验